Prevention of Periprosthetic Bone Loss After Total Hip Replacement by Annual Bisphosphonate Therapy

NCT02838121 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

62

Enrollment

OTHER

Sponsor class

Conditions

Prevention of BMD Loss After THR
Serum Markers of Bone Turnover
Functional Outcomes

Interventions

DRUG: Aclasta
DRUG: Placebo

Sponsor

Mel Shiuann-Sheng Lee

Collaborators

[object Object]